Compare GWW & INSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GWW | INSM |
|---|---|---|
| Founded | 1927 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.4B | 41.2B |
| IPO Year | N/A | 2000 |
| Metric | GWW | INSM |
|---|---|---|
| Price | $1,027.82 | $176.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 21 |
| Target Price | ★ $1,016.67 | $185.84 |
| AVG Volume (30 Days) | 291.9K | ★ 3.7M |
| Earning Date | 01-30-2026 | 10-30-2025 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 35.69 | N/A |
| Revenue | ★ $17,750,000,000.00 | $447,022,000.00 |
| Revenue This Year | $5.42 | $43.95 |
| Revenue Next Year | $5.06 | $130.35 |
| P/E Ratio | $28.70 | ★ N/A |
| Revenue Growth | 4.83 | ★ 30.34 |
| 52 Week Low | $893.99 | $60.40 |
| 52 Week High | $1,139.15 | $212.75 |
| Indicator | GWW | INSM |
|---|---|---|
| Relative Strength Index (RSI) | 63.59 | 39.37 |
| Support Level | $1,016.74 | $172.65 |
| Resistance Level | $1,039.75 | $179.44 |
| Average True Range (ATR) | 19.18 | 6.58 |
| MACD | 1.12 | -2.69 |
| Stochastic Oscillator | 83.09 | 34.58 |
Founded in 1927, W.W. Grainger originally distributed various motors via a mail-order catalogue. Over the course of the 20th century, the firm expanded into new industrial product categories and launched its first digital catalogue in 1995. Today, the company organizes itself into two segments focused on different customer bases. Its larger segment, high-touch solutions, offers a vast array of maintenance, repair, and operations, or MRO, supplies and bespoke inventory management services to larger businesses. Its smaller segment, endless assortment, operates two online platforms, Zoro and MonotaRO, that offer comprehensive catalogues of MRO supplies to smaller businesses. Grainger has operations throughout the world but primarily generates sales within the US.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.